{"prompt": "['Product: MK-3475', '105', 'Protocol/Amendment No.: 604-09', '8.6', 'Statistical Methods', '8.6.1 Statistical Methods for Efficacy Analyses', 'This section describes the statistical methods that address the primary and secondary', 'objectives. Methods related to exploratory objectives will be described in the sSAP.', 'Efficacy results that will be deemed to be statistically significant after consideration of the', 'Type I error control strategy are described in Section 8.8. Nominal p-values will be computed', 'for other efficacy analyses, but should be interpreted with caution due to potential issues of', 'multiplicity.', '8.6.1.1 Progression-free Survival', 'The non-parametric Kaplan-Meier method will be used to estimate the PFS curve in each', 'treatment group. The treatment difference in PFS will be assessed by the stratified log-rank', 'test (based on the stratification factors defined in Section 5.4). A stratified Cox proportional', \"hazard model with Efron's method of tie handling will be used to assess the magnitude of the\", 'treatment difference (ie, the hazard ratio [HR]) between the treatment arms. The HR and its', \"95% CI from the stratified Cox model with Efron's method of tie handling and with a single\", 'treatment covariate will be reported. The stratification factors used for randomization (See', 'Section 5.4) will be applied to both the stratified log-rank test and the stratified Cox model.', 'Since disease progression is assessed periodically, PD can occur any time in the time interval', 'between the last assessment where PD was not documented and the assessment when PD is', 'documented. For the primary analysis, for the subjects who have PD, the true date of disease', 'progression will be approximated by the date of the first assessment at which PD is', 'objectively documented as assessed by BICR per RECIST 1.1 modified to follow a', 'maximum of 10 target lesions and a maximum of 5 target lesions per organ, regardless of', 'discontinuation of study drug. Death is always considered as a confirmed PD event.', 'In order to evaluate the robustness of the PFS endpoint per modified RECIST 1.1 by central', 'imaging vendor, we will perform 2 sensitivity analyses with a different set of censoring rules.', 'The first sensitivity analysis is the same as the primary analysis except that data for any', 'subject who misses more than one disease assessment (with or without a subsequent death or', 'progression) are censored at the last disease assessment prior to missing visits. The second', 'sensitivity analysis is the same as the primary analysis except that it considers', 'discontinuation of treatment or initiation of an anticancer treatment subsequent to', 'discontinuation of study-specified treatments, whichever occurs later, to be a PD event for', 'subjects without documented PD or death. If a subject meets multiple criteria for censoring,', 'the censoring criterion that occurs earliest will be applied. The censoring rules for primary', 'and sensitivity analyses are summarized in Table 11.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '106', 'Protocol/Amendment No.: 604-09', 'Table 11', 'Censoring Rules for Primary and Sensitivity Analyses of Progression-free', 'Survival', 'Sensitivity', 'Sensitivity', 'Situation', 'Primary Analysis', 'Analysis 1', 'Analysis 2', 'No PD and no death;', 'Censored at last', 'Censored at last disease', 'Censored at last disease', 'new anticancer', 'disease assessment', 'assessment', 'assessment if still on study', 'treatment is not', 'therapy; progressed at', 'initiated', 'treatment discontinuation', 'otherwise', 'No PD and no death;', 'Censored at last', 'Censored at last disease', 'Progressed at date of new', 'new anticancer', 'disease assessment', 'assessment before new', 'anticancer treatment', 'treatment is initiated', 'before new anticancer', 'anticancer treatment', 'treatment', 'No PD and no death;', 'Censored at last', 'Censored at last disease', 'Censored at last disease', '>2 consecutive missed', 'disease assessment', 'assessment prior to >2', 'assessment', 'disease assessments', 'consecutive missed', 'visits', 'PD or death', 'Progressed at date of', 'Progressed at date of', 'Progressed at date of', 'documented after', 'documented PD or', 'documented PD or', 'documented PD or death', '<1 missed disease', 'death', 'death', 'assessment', 'PD or death', 'Progressed at date of', 'Censored at last disease', 'Progressed at date of', 'documented at any', 'documented PD or', 'assessment prior to the', 'documented PD or death', 'time after >2 missed', 'death', '>2 missed disease', 'disease assessments', 'assessment', '8.6.1.2 Overall Survival', 'The non-parametric Kaplan-Meier method will be used to estimate the survival curves. The', 'treatment difference in survival will be assessed by the stratified log-rank test (based on the', 'stratification factor defined in Section 5.4). A stratified Cox proportional hazard model with', \"Efron's method of tie handling will be used to assess the magnitude of the treatment\", 'difference (ie, the HR). The HR and its 95% CI from the stratified Cox model with a single', 'treatment covariate will be reported. The stratification factors used for randomization (See', 'Section 5.4) will be applied to both the stratified log-rank test and the stratified Cox model.', 'Restricted Mean Survival Time (RMST) method may be conducted for OS to account for the', 'possible non-proportional hazards effect.', 'Since subjects in the placebo+EP arm are expected to discontinue from the study earlier', 'compared to subjects in the pembrolizumab arm because of earlier onset of PD and may', 'switch to another anti PD-1 treatment following confirmation of PD, adjustment for the effect', 'of crossover on os may be performed based on recognized methods, (eg, the Rank', 'Preserving Structural Failure Time (RPSFT) model proposed by Robins and Tsiatis [115]),', 'based on an examination of the appropriateness of the data to the assumptions required by the', 'method used.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}